677. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum Potassium and Clinical Outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118(16):1643-50. doi: 10.1161/CIRCULATIONAHA.108.778811.

678. Varshney AS, Singh JP, Vaduganathan M. A Heart Team Approach to Contemporary Device Decision-making in Heart Failure. Eur J Heart Fail. 2022;24(3):562-4. doi: 10.1002/ejhf.2445.

679. Effect of Metoprolol CR/XL in Chronic Heart Failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7.

680. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of Carvedilol on the Morbidity of Patients with Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002;106(17):2194-9. doi: 10.1161/01.cir.0000035653.72855.bf.

681. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomised Trial. Lancet. 1999;353(9146):9-13.

682. Botoni FA, Poole-Wilson PA, Ribeiro ALP, Okonko DO, Oliveira BM, Pinto AS, et al. A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy. Am Heart J. 2007;153(4):544-1. doi: 10.1016/j.ahj.2006.12.017.

683. Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, et al. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. JACC Heart Fail. 2020;8(10):844-55. doi: 10.1016/j.jchf.2020.06.015.

684. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(41):2793-867. doi: 10.1093/eurheartj/ehv316.

685. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an Implantable Cardioverter-defibrillator for Congestive Heart Failure. N Engl J Med. 2005;352(3):225-37. doi: 10.1056/NEJMoa043399.

686. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ. Randomised Trial of Effect of Amiodarone on Mortality in Patients with Left-ventricular Dysfunction After Recent Myocardial Infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997;349(9053):667-74. doi: 10.1016/s0140-6736(96)09145-3.

687. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised Trial of Low-dose Amiodarone in Severe Congestive Heart Failure. Lancet. 1994;344(8921):493-8. doi: 10.1016/s0140-6736(94)91895-3.

688. Amiodarone Trials Meta-Analysis Investigators. Effect of Prophylactic Amiodarone on Mortality After Acute Myocardial Infarction and in Congestive Heart Failure: Meta-analysis of Individual Data from 6500 Patients in Randomised Trials. Lancet. 1997;350(9089):1417-24.

689. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative Overview of Randomized Trials of Amiodarone to Prevent Sudden Cardiac Death. Circulation. 1997;96(9):2823-9. doi: 10.1161/01.cir.96.9.2823.

690. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333(2):77-82. doi: 10.1056/NEJM19950713330201.

691. Garguichevich JJ, Ramos JL, Gambarte A, Gentile A, Hauad S, Scapin O, et al. Effect of Amiodarone Therapy on Mortality in Patients with Left Ventricular Dysfunction and Asymptomatic Complex Ventricular Arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J. 1995;130(3):494-500. doi: 10.1016/0002-8703(95)90357-7.

692. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone Versus Implantable Cardioverter-defibrillator: Randomized Trial in patients with Nonischemic Dilated Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia-AMIOVIRT. J Am Coll Cardiol. 2003;41(10):1707-12. doi: 10.1016/s0735-1097(03)00297-3.

693. Poole JE, Olshansky B, Mark DB, Anderson J, Johnson G, Hellkamp AS, et al. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. J Am Coll Cardiol. 2020;76(4):405-15. doi: 10.1016/j.jacc.2020.05.061.

694. Piccini JP, Berger JS, O'Connor CM. Amiodarone for the Prevention of Sudden Cardiac Death: A Meta-analysis of Randomized Controlled Trials. Eur Heart J. 2009;30(10):1245-53. doi: 10.1093/eurheartj/ehp100.

695. Claro JC, Candia R, Rada G, Baraona F, Larrondo F, Letelier LM. Amiodarone Versus Other Pharmacological Interventions for Prevention of Sudden Cardiac Death. Cochrane Database Syst Rev. 2015;2015(12):CD008093. doi: 10.1002/14651858.CD008093.pub2.

696. Sousa MR, Morillo CA, Rabelo FT, Nogueira Filho AM, Ribeiro ALP. Non-sustained Ventricular Tachycardia as a Predictor of Sudden Cardiac Death in Patients with Left Ventricular Dysfunction: A Meta-analysis. Eur J Heart Fail. 2008;10(10):1007-14. doi: 10.1016/j.ejheart.2008.07.002.

697. Lehmann MH, Steinman RT, Meissner MD, Schuger CD, Mosteller RD, Nabih MA. Need for a Standardized Approach to Grading Symptoms Associated with Ventricular Tachyarrhythmias. Am J Cardiol. 1991;67(16):1421-3. doi: 10.1016/0002-9149(91)90474-y.

698. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A Comparison of Antiarrhythmic Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-fatal Ventricular Arrhythmias. N Engl J Med. 1997;337:1576-83. doi: 10.1056/NEJM199711273372202.

699. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon R, et al. Canadian Implantable Defibrillator Study (CIDS): A Randomized Trial of the Implantable Defibrillator Against Amiodarone. Circulation. 2000;101(11):1297-302. doi: 10.1161/01.cir.101.11.1297.

700. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized Comparison of Antiarrhythmic Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Cardiac Arrest. Circulation. 2000;102(7):748-54. doi: 10.1161/01.cir.102.7.748.

701. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the Implantable Cardioverter Defibrillator Secondary Prevention Trials. Antiarrhythmics vs Implantable Defibrillator Study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071-8. doi: 10.1053/euhj.2000.2476.

702. Raitt MH, Renfroe EG, Epstein AE, McAnulty JH, Mounsey P, Steinberg JS, et al. "Stable" Ventricular Tachycardia is not a Benign Rhythm: Insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry. Circulation. 2001;103(2):244-52. doi: 10.1161/01.cir.103.2.244.

703. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):1677-749. doi: 10.1016/j.jacc.2017.10.053.

704. Carrasco HA, Guerrero L, Parada H, Molina C, Vegas E, Chuecos R. Ventricular Arrhythmias and Left Ventricular Myocardial Function in Chronic Chagasic Patients. Int J Cardiol. 1990;28(1):35-41. doi: 10.1016/0167-5273(90)90006-q.

705. Brugada P. Chagas' Disease and Tachycardiomyopathy. Arq Bras Cardiol. 1991;56(1):5-7.

706. Huizar JF, Fisher SG, Ramsey FV, Kaszala K, Tan AY, Moore H, et al. Outcomes of Premature Ventricular Contraction-cardiomyopathy in the Veteran Population: A Secondary Analysis of the CHF-STAT Study. JACC Clin Electrophysiol. 2021;7(3):380-90. doi: 10.1016/j.jacep.2020.08.028.
707. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-8. doi: 10.1056/NEJM199103213241201.

708. Stein C, Migliavaca CB, Colpani V, Rosa PR Sganzerla D, Giordani NE, et al. Amiodarone for Arrhythmia in Patients with Chagas Disease: A Systematic Review and Individual Patient Data Meta-analysis. PLoS Negl Trop Dis. 2018;12(8):e0006742. doi: 10.1371/journal.pntd.0006742.

709. Scanavacca MI, Sosa EA, Lee JH, Bellotti G, Pileggi F. Empiric Therapy with Amiodarone in Patients with Chronic Chagas Cardiomyopathy and Sustained Ventricular Tachycardia. Arq Bras Cardiol. 1990;54(6):367-71.

710. Sarabanda AV, Marin-Neto JA. Predictors of Mortality in Patients with Chagas' Cardiomyopathy and Ventricular Tachycardia not Treated with Implantable Cardioverter-defibrillators. Pacing Clin Electrophysiol. 2011;34(1):54-62. doi: 10.1111/j.1540-8159.2010.02896.x.

711. Connolly SJ. Evidence-based Analysis of Amiodarone Efficacy and Safety. Circulation. 1999;100(19):2025-34. doi: 10.1161/01.cir.100.19.2025.

712. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse Effects of Low Dose Amiodarone: A Meta-analysis. J Am Coll Cardiol. 1997;30(3):791-8. doi: 10.1016/s0735-1097(97)00220-9.

713. Ruzieh M, Moroi MK, Aboujamous NM, Ghahramani M, Naccarelli GV, Mandrola J, et al. Meta-analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo. Am J Cardiol. 2019;124(12):1889-93. doi: 10.1016/j.amjcard.2019.09.008.

714. Siddoway LA. Amiodarone: Guidelines for Use and Monitoring. Am Fam Physician. 2003;68(11):218996.

715. Muratore CA, Sa LAB, Chiale PA, Eloy R, Tentori MC, Escudero J, et al. Implantable Cardioverter Defibrillators and Chagas' Disease: Results of the ICD Registry Latin America. Europace. 2009;11(2):164-8. doi: 10.1093/europace/eun325.

716. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of Beta-blockers, Amiodarone Plus Beta-blockers, or Sotalol for Prevention of Shocks from Implantable Cardioverter Defibrillators: The OPTIC Study: A Randomized Trial. JAMA. 2006;295(2):165-71. doi: 10.1001/jama.295.2.165.

717. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study. Circulation. 2003;107(23):2920-5. doi: 10.1161/01.CIR.0000072767.89944.6E.

718. Gopinathannair R, Chen LY, Chung MK, Cornwell WK, Furie KL, Lakkireddy DR, et al. Managing Atrial Fibrillation in Patients with Heart Failure and Reduced Ejection Fraction: A Scientific Statement from the American Heart Association. Circ Arrhythm Electrophysiol. 2021;14(6):HAE000000000000078. doi: 10.1161/HAE.00000000000000078.

719. Rojas LZ, Glisic M, Pletsch-Borba L, Echeverría LE, Bramer WM, Bano A, et al. Electrocardiographic Abnormalities in Chagas Disease in the General Population: A Systematic Review and Meta-analysis. PLoS Negl Trop Dis. 2018;12(6):e0006567. doi: 10.1371/journal.pntd.0006567.

720. Cardoso R, Garcia D, Fernandes G, He LI, Lichtenberger P, Viles-Gonzalez J, et al. The Prevalence of Atrial Fibrillation and Conduction Abnormalities in Chagas' Disease: A Meta-analysis. J Cardiovasc Electrophysiol. 2016;27(2):161-9. doi: 10.1111/jce.12845.

721. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of Atrial Fibrillation with Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-analysis. J Am Coll Cardiol. 2005;45(11):1832-9. doi: 10.1016/j.jacc.2004.11.070.

722. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.

723. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-27. doi: 10.1056/NEJMoa1707855.

724. Mateos JCP, Lobo TJ, Mateos EIP. Aspectos Eletrofisiológicos da Cardiopatia Chagásica. Rev Soc Cardiol Estado de São Paulo. 2009;19(1):39-50.

725. Acquatella H, Catalioti F, Gomez-Mancebo JR, Davalos V, Villalobos L. Long-term Control of Chagas Disease in Venezuela: Effects on Serologic Findings, Electrocardiographic Abnormalities, and Clinical Outcome. Circulation. 1987;76(3):556-62. doi: 10.1161/01.cir.76.3.556.

726. Nacruth RS, Benini N, Bongiovani AC. Bloqueios Divisionais na Doença de Chagas. Rev Soc Bras Med Trop. 1987;20:19.

727. Garzon SA, Lorga AM, Nicolau JC. Electrocardiography in Chagas' Heart Disease. Sao Paulo Med J. 1995;113(2):802-13. doi: 10.1590/s1516-31801995000200011.

728. Pachon-Mateos JC, Pereira WL, Batista WD Jr, Mateos JCP, Mateo EIP, Vargas RNA, et al. RBM - Registro Brasileiro de Marcapassos, Ressincronizadores e Desfibradores. Relampa. 2013;26(1):39-49.

729. Arce M, Van Grieken J, Femenía F, Arrieta M, McIntyre WF, Baranchuk A. Permanent Pacing in Patients with Chagas' Disease. Pacing Clin Electrophysiol. 2012;35(12):1494-7. doi: 10.1111/pace.12013.

730. Scanavacca M, Sosa E. Electrophysiologic Study in Chronic Chagas' Heart Disease. Sao Paulo Med. J. 113(2):168-76. doi: 10.1590/S1516-31801995000200016.

731. Peixoto GL, Martinelli Filho M, Siqueira SF, Nishioka SAD, Pedrosa AAA, Teixeira RA, et al. Predictors of Death in Chronic Chagas Cardiomyopathy Patients with Pacemaker. Int J Cardiol. 2018;250:260-5. doi: 10.1016/j.ijcard.2017.10.031.

732. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual-chamber Pacing or Ventricular Backup Pacing in Patients with an Implantable Defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288(24):3115-23. doi: 10.1001/jama.288.24.3115.

733. Sharma AD, Rizo-Patron C, Hallstrom AP, O'Neill GP, Rothbart S, Martins JB, et al. Percent Right Ventricular Pacing Predicts Outcomes in the DAVID Trial. Heart Rhythm. 2005;2(8):830-4. doi: 10.1016/j.hrthm.2005.05.015.

734. Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL, Pedersen AK. A Randomized Comparison of Atrial and Dual-chamber Pacing in 177 Consecutive Patients with Sick Sinus Syndrome: Echocardiographic and Clinical Outcome. J Am Coll Cardiol. 2003;42(4):614-23. doi: 10.1016/s0735-1097(03)00757-5.

735. Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, et al. Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular Pacing. J Am Coll Cardiol. 2018;71(20):2319-30. doi: 10.1016/j.jacc.2018.02.048.

736. Wu S, Su L, Vijayaraman P, Zheng R, Cai M, Xu L, et al. Left Bundle Branch Pacing for Cardiac Resynchronization Therapy: Nonrandomized On-treatment Comparison with His Bundle Pacing and Biventricular Pacing. Can J Cardiol. 2021;37(2):319-28. doi: 10.1016/j.cjca.2020.04.037.

737. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(7):51-156. doi: 10.1016/j.jacc.2018.10.044.

738. Abello M, González-Zuelgaray J, López C, Labadet C. Initiation Modes of Spontaneous Monomorphic Ventricular Tachycardia in Patients with Chagas Heart Disease. Rev Esp Cardiol. 2008;61(5):487-93.

739. Cardinalli-Neto A, Nakazone MA, Grassi LV, Tavares BG, Bestetti RB. Implantable Cardioverter-defibrillator Therapy for Primary Prevention of Sudden Cardiac Death in Patients with Severe Chagas Cardiomyopathy. Int J Cardiol. 2011;150(1):94-5. doi: 10.1016/j.ijcard.2011.03.036.
740. Muratore C, Rabinovich R, Iglesias R, González M, Darú V, Liprandi AS. Implantable Cardioverter Defibrillators in Patients with Chagas' Disease: Are They Different from Patients with Coronary Disease? Pacing Clin Electrophysiol. 1997;20(1):194-7. doi: 10.1111/j.1540-8159.1997.tb04841.x.

741. Garillo R, Greco OT, Oseroff O, Lucchese F, Fuganti C, Montenegro JL, et al. Cardiodesfibrilador Implantable como Prevención Secundaria en la Enfermedad de Chagas. Los resultados del Estudio Latinoamericano ICD-LABOR. Reblampa 2004;17:169-77.

742. Fonseca SM, Belo LG, Carvalho H, Araújo N, Munhoz C, Siqueira L, et al. Clinical Follow-up of Patients with Implantable Cardioverter-defibrillator. Arq Bras Cardiol 2007;88(1):8-16. doi: 10.1590/s0066-782x2007000100002.

743. Cardinalli-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of All-cause Mortality for Patients with Chronic Chagas' Heart Disease Receiving Implantable Cardioverter Defibrillator Therapy. J Cardiovasc Electrophysiol 2007;18(12):1236-40. doi: 10.1111/j.1540-8167.2007.00954.x.

744. Flores-Ocampo J, Nava S, Márquez MF, Gómez-Flores J, Colín L, López A, et al. Predictores Clínicos de Tormenta Arrítmica en Pacientes con Cardiomiopatía Chagásica con um Desfibrilador Automático Implantable. Arch Cardiol Mex. 2009;79(4):263-7.

745. Toro D, Muratore C, Aguinaga L, Batista L, Malan A, Greco O, et al. Predictors of All-cause 1-year Mortality in Implantable Cardioverter Defibrillator Patients with Chronic Chagas' Cardiomyopathy. Pacing Clin Electrophysiol 2011;34(9):1063-9. doi: 10.1111/j.1540-8159.2011.03108.x.

746. Martinelli M, Siqueira SF, Sternick EB, Rassi A Jr, Costa R, Ramires JA, et al. Long-term follow-up of Implantable Cardioverter Defibrillator for Secondary Prevention in Chagas' Heart Disease. Am J Cardiol 2012;110(7):1040-5. doi: 10.1016/j.amjcard.2012.05.040.

747. Gali WL, Sarabanda AV, Baggio JM, Ferreira LG, Gomes GG, Marin-Neto JA, et al. Implantable Cardioverter-defibrillators for Treatment of Sustained Ventricular Arrhythmias in Patients with Chagas' Heart Disease: Comparison with a Control Group Treated with Amiodarone Alone. Europace. 2014;16(5):674-80. doi: 10.1093/europace/eut422.

748. Pereira FT, Rocha EA, Monteiro MP, Neto AC, Daher EF, Sobrinho CR, et al. Long-term follow-up of Patients with Chronic Chagas Disease and Implantable Cardioverter-defibrillator. Pacing Clin Electrophysiol. 2014;37(6):751-6. doi: 10.1111/pace.12342.

749. Pavão MLRC, Arfelli E, Scorzoni-Filho A, Rassi A Jr, Pazin-Filho A, Pavão RB, et al. Long-term Follow-up of Chagas Heart Disease Patients Receiving an Implantable Cardioverter-defibrillator for Secondary Prevention. Pacing Clin Electrophysiol. 2018;41(6):583-8. doi: 10.1111/pace.13333.

750. Melo RMV, Azevedo DFC, Lira YM, Oliveira NFC, Passos LCS. Chagas Disease is Associated with a Worse Prognosis at 1-year Follow-up After Implantable Cardioverter-defibrillator for Secondary Prevention in Heart Failure Patients. J Cardiovasc Electrophysiol. 2019;30(11):2448-52. doi: 10.1111/jce.14164.

751. Carmo AA, Sousa MR, Agudelo JF, Boersma E, Rocha MO, Ribeiro ALP, et al. Implantable Cardioverter-defibrillator in Chagas Heart Disease: A Systematic Review and Meta-analysis of Observational Studies. Int J Cardiol. 2018;267:88-93. doi: 10.1016/j.ijcard.2018.05.091.

752. Rassi FM, Minohara L, Rassi Jr A, Correia LC, Marin-Neto JA, Rassi A, et al. Systematic Review and Meta-analysis of Clinical Outcome After Implantable Cardioverter-defibrillator Therapy in Patients with Chagas Heart Disease. JACC: Clinical Electrophysiology. 2019;5(10):1213-23. doi: 10.1016/j.jacep.2019.07.003.

753. Lima CEB, Martinelli Filho M, Silva RT, Guirão CI, Nishioka SD, Pedrosa AAA, et al. Efetividade do CDI na Taquicardia Ventricular Sincopal e na Parada Cardíaca. Relampa 2009;22(3):143-51.

754. Leite LR, Fenelon G, Paes AT, Paola AA. The Impact of Syncope During Clinical Presentation of Sustained Ventricular Tachycardia on Total and Cardiac Mortality in Patients with Chronic Chagasic Heart Disease. Arq Bras Cardiol. 2001;77(5):439-52. doi: 10.1590/s0066-782x2001001100005.

755. Zeppenfeld K, Tfelt-Hansen J, Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Eur Heart J. 2022;ehac262. doi: 10.1093/eurheartj/ehac262.

756. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. N Engl J Med. 2005;352(15):1539-49. doi: 10.1056/NEJMoa050496.

757. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac Resynchronization in Chronic Heart Failure. N Engl J Med. 2002;346(24):1845-53. doi: 10.1056/NEJMoa013168.

758. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac Resynchronization Therapy for the Treatment of Heart Failure in Patients with Intraventricular Conduction Delay and Malignant Ventricular Tachyarrhythmias. J Am Coll Cardiol. 2003;42(8):1454-9. doi: 10.1016/s0735-1097(03)01042-8.

759. Kuniyoshi RR, Martinelli M, Negrao CE, Siqueira SF, Rondon MU, Trombetta IC, et al. Effects of Cardiac Resynchronization Therapy on Muscle Sympathetic Nerve Activity. Pacing Clin Electrophysiol. 2014;37(1):11-8. doi: 10.1111/pace.12254.

760. Spaggiari CV, Kuniyoshi RR, Antunes-Correa LM, Groehs RV, Siqueira SF, Martinelli Filho M. Cardiac Resynchronization Therapy Restores Muscular Metaboreflex Control. J Cardiovasc Electrophysiol. 2019;30(11):2591-8. doi: 10.1111/jce.14195.

761. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert J P, et al. Cardiac-resynchronization Therapy for the Prevention of Heart-failure Events. N Engl J Med. 2009;361(14):1329-38. doi: 10.1056/NEJMoa0906431.

762. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-Resynchronization Therapy for Mild-to-moderate Heart Failure. N Engl J Med. 2010;363(25):2385-95. doi: 10.1056/NEJMoa1009540.

763. Van Bommel RJ, Bax JJ, Abraham WT, Chung ES, Pires LA, Tavazzi L, et al. Characteristics of Heart Failure Patients Associated with Good and Poor Response to Cardiac Resynchronization Therapy: A PROSPECT (Predictors of Response to CRT) Sub-analysis. Eur Heart J. 2009;30(20):2470-7. doi: 10.1093/eurheartj/ehp368.

764. Di Biase L, Auricchio A, Mohanty P, Bai R, Kautzner J, Pieragnoli P, et al. Impact of Cardiac Resynchronization Therapy on the Severity of Mitral Regurgitation. Europace. 2011;13(6):829-38. doi: 10.1093/europace/eur047.

765. Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late Gadolinium Enhancement by Cardiovascular Magnetic Resonance Heralds an Adverse Prognosis in Nonischemic Cardiomyopathy. J Am Coll Cardiol. 2008;51(25):2414-21. doi: 10.1016/j.jacc.2008.03.018.

766. Hussain MA, Furuya-Kanamori L, Kaye G, Clark J, Doi SA. The Effect of Right Ventricular Apical and Nonapical Pacing on the Short-and Long-term Changes in Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis of Randomized-controlled Trials. Pacing Clin Electrophysiol. 2015;38(9):1121-36. doi: 10.1111/pace.12681.

767. Shimony A, Eisenberg MJ, Filion KB, Amit G. Beneficial Effects of Right Ventricular Non-apical vs. Apical Pacing: A Systematic Review and Meta-analysis of Randomized-Controlled Trials. Europace. 2012;14(1):81-91. doi: 10.1093/europace/eur240.

768. Araújo EF, Chamlian EG, Peroni AP, Pereira WL, Gandra SM, Rivetti LA. Cardiac Resynchronization Therapy in Patients with Chronic Chagas Cardiomyopathy: Long-term Follow Up. Rev Bras Cir Cardiovasc. 2014;29(1):31-6. doi: 10.5935/1678-9741.20140008.

769. Menezes ADS Jr, Lopes CC, Cavalcante PF, Martins E. Chronic Chagas Cardiomyopathy Patients and Resynchronization Therapy: A Survival Analysis. Braz J Cardiovasc Surg. 2018;33(1):82-8. doi: 10.21470/1678-9741-2017-0134.

770. Martinelli Filho M, Peixoto GL, Siqueira SF, Martins SAM, Nishioka SAD, Pedrosa AAA, et al. A Cohort Study of Cardiac Resynchronization Therapy in Patients with Chronic Chagas Cardiomyopathy. Europace. 2018;20(11):1813-8. doi: 10.1093/europace/eux375.
771. Scorzoni Filho A. Terapia de Ressincronização Cardíaca nas Cardiomiopatias Chagásica e Não Chagásicas [dissertation]. Ribeirão Preto: Faculdade de Medicina da Universidade de São Paulo; 2018.

772. Passos LCS, Melo RMV, Lira YM, Oliveira NFC, Trindade T, Carvalho W, et al. Chagas Disease is Associated with a Poor Outcome at 1-year Follow-up After Cardiac Resynchronization Therapy. Rev Assoc Med Bras. 2019;65(11):1391-6. doi: 10.1590/1806-9282.65.11.1391.

773. Martinelli Filho M, Siqueira SF, Costa R, Greco OT, Moreira LF, D'Avila A, et al. Conventional Versus Biventricular Pacing in Heart Failure and Bradyarrhythmia: The COMBAT Study. J Card Fail. 2010;16(4):293-300. doi: 10.1016/j.cardfail.2009.12.008.

774. Gierula J, Cubbon RM, Jamil HA, Byrom R, Baxter PD, Pavitt S, et al. Cardiac Resynchronization Therapy in Pacemaker-dependent Patients with Left Ventricular Dysfunction. Europace. 2013;15(11):1609-14. doi: 10.1093/ europace/eut148.

775. Marin-Neto JA, Simões MV, Sarabanda AV. Chagas' Heart Disease. Arq Bras Cardiol. 1999;72(3):247-80. doi: 10.1590/s0066-782x1999000300001.

776. Sarabanda AV, Sosa E, Simões MV, Figueiredo GL, Pintya AO, Marin-Neto JA. Ventricular Tachycardia in Chagas' Disease: A Comparison of Clinical, Angiographic, Electrophysiologic and Myocardial Perfusion Disturbances Between Patients Presenting with Either Sustained or Nonsustained Forms. Int J Cardiol. 2005;102(1):9-19. doi: 10.1016/j.ijcard.2004.03.087.

777. Sosa E, Scanavacca M, D'Avila A, Piccioni J, Sanchez O, Velarde JL, et al. Endocardial and Epicardial Ablation Guided by Nonsurgical Transthoracic Epicardial Mapping to Treat Recurrent Ventricular Tachycardia. J Cardiovasc Electrophysiol. 1998;9(3):229-39. doi: 10.1111/j.1540-8167.1998. tb00907.x.

778. Sosa E, Scanavacca M, D'Avila A, Bellotti G, Pilleggi F. Radiofrequency Catheter Ablation of Ventricular Tachycardia Guided by Nonsurgical Epicardial Mapping in Chronic Chagasic Heart Disease. Pacing Clin Electrophysiol. 1999;22(1):128-30. doi: 10.1111/j.1540-8159.1999.tb00311.x.

779. Henz BD, Nascimento TA, Dietrich CO, Dalegrave C, Hernandes V, Mesas CE, et al. Simultaneous Epicardial and Endocardial Substrate Mapping and Radiofrequency Catheter Ablation as First-line Treatment for Ventricular Tachycardia and Frequent ICD Shocks in Chronic Chagasic Cardiomyopathy. J Interv Card Electrophysiol. 2009;26(3):195-205. doi: 10.1007/s10840- 009-9433-4.

780. Soto-Becerra R, Bazan V, Bautista W, Malavassi F, Altamar J, Ramirez JD, et al. Ventricular Tachycardia in the Setting of Chagasic Cardiomyopathy: Use of Voltage Mapping to Characterize Endoepicardial Nonischemic Scar Distribution. Circ Arrhythm Electrophysiol. 2017;10(11):e004950. doi: 10.1161/CIRCEP.116.004950.

781. Pisani CF, Romero J, Lara S, Hardy C, Chokr M, Sacilotto L, et al. Efficacy and Safety of Combined Endocardial/Epicardial Catheter Ablation for Ventricular Tachycardia in Chagas Disease: A Randomized Controlled Study. Heart Rhythm. 2020;17(9):1510-8. doi: 10.1016/j.hrthm.2020.02.009.

782. Scanavacca M, Sosa E, D'Avila A, Higuchi ML. Radiofrequency Ablation of Sustained Ventricular Tachycardia Related to the Mitral Isthmus in Chagas' Disease. Pacing Clin Electrophysiol. 2002;25(3):368-71. doi: 10.1046/j.1460-9592.2002.00368.x.

783. Sarabanda AV, Gali WL, Gomes GG. Bundle Branch Reentry: A Novel Mechanism for Sustained Ventricular Tachycardia in Chagas Heart Disease. HeartRhythm Case Rep. 2018;4(7):293-7. doi: 10.1016/j. hcr.2018.03.009.

784. Santos AM, Scanavacca MI, Darrieux F, Ianni B, Melo SL, Pisani C, et al. Baroreflex Sensitivity and its Association with Arrhythmic Events in Chagas Disease. Arq Bras Cardiol. 2014;102(6):579-87. doi: 10.5935/ abc.20140066.

785. Saenz LC, Corrales FM, Bautista W, Traina M, Meymandi S, Rodriguez DA, et al. Cardiac Sympathetic Denervation for Intractable Ventricular Arrhythmias in Chagas Disease. Heart Rhythm. 2016;13(7):1388-94. doi: 10.1016/j. hrthm.2016.03.014.

786. Téllez LJ, Garzón JC, Vinck EE, Castellanos JD. Video-assisted Thoracoscopic Cardiac Denervation of Refractory Ventricular Arrhythmias and Electrical Storms: A Single-center Series. J Cardiothorac Surg. 2019;14(1):17. doi: 10.1186/s13019-019-0838-6.

787. Armaganijan LV, Staico R, Moreira DA, Lopes RD, Medeiros PT, Habib R, et al. 6-month Outcomes in Patients with Implantable Cardioverter-defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. JACC Cardiovasc Interv. 2015;8(7):984-90. doi: 10.1016/j.jcin.2015.03.012.

788. Shapiro H, Meymandi S, Shivkumar K, Bradfield JS. Cardiac Inflammation and Ventricular Tachycardia in Chagas Disease. HeartRhythm Case Rep. 2017;3(8):392-5. doi: 10.1016/j.hcr.2017.05.007.

789. Santangeli P, Muser D, Zado ES, Magnani S, Khetpal S, Hutchinson MD, et al. Acute Hemodynamic Decompensation During Catheter Ablation of Scar-related Ventricular Tachycardia: Incidence, Predictors, and Impact on Mortality. Circ Arrhythm Electrophysiol. 2015;8(1):68-75. doi: 10.1161/ CIRCEP.114.002155.

790. Santangeli P, Frankel DS, Tung R, Vaseghi M, Sauer WH, Tzou WS, et al. Early Mortality After Catheter Ablation of Ventricular Tachycardia in Patients with Structural Heart Disease. J Am Coll Cardiol. 2017;69(17):2105-15. doi: 10.1016/j.jacc.2017.02.044.

791. Kulchetscki RM, Pisani CF, Alexandre FKB, Mayrink MP, Ferraz AP, Gouvea FC, et al. Applicability of the PAINESD Risk Score for 30-day Mortality Prediction Post Ventricular Tachycardia Catheter Ablation in Chagas Disease. J Interv Card Electrophysiol. 2021;62(3):469-77. doi: 10.1007/s10840-021- 00995-z.

792. Lopes ER, Rocha A, Meneses AC, Lopes MA, Fatureto MC, Lopes GP, et al. Prevalence of Visceromegali in Necropsies Carried Out in Triângulo Mineiro from 1954 to 1988. Rev Soc Bras Med Trop. 1989;22(4):211-5. doi: 10.1590/s0037-86821989000400008.

793. Silveira AB, Lemos EM, Adad SJ, Correa-Oliveira R, Furness JB, Reis DA. Megacolon in Chagas Disease: A Study of Inflammatory Cells, Enteric Nerves, and Glial Cells. Hum Pathol. 2007;38(8):1256-64. doi: 10.1016/j. humpath.2007.01.020.

794. Romero J, Velasco A, Pisani CF, Alviz I, Briceno D, Díaz JC, et al. Advanced Therapies for Ventricular Arrhythmias in Patients with Chagasic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77(9):1225-42. doi: 10.1016/j.jacc.2020.12.056.

795. Carmo AAL, Zenobio S, Santos BC, Rocha MOC, Ribeiro ALP. Feasibility and Safety of Laparoscopic-guided Epicardial Access for Ventricular Tachycardia Ablation. J Am Heart Assoc. 2020;9(15):e016654. doi: 10.1161/JAHA.120.016654.

796. Rochitte CE, Nacif MS, Oliveira AC Jr, Siqueira-Batista R, Marchiori E, Uellendahl M, et al. Cardiac Magnetic Resonance in Chagas' Disease. Artif Organs. 2007;31(4):259-67. doi: 10.1111/j.1525-1594.2007.00373.x.

797. Bogun FM, Desjardins B, Good E, Gupta S, Crawford T, Oral H, et al. Delayed-enhanced Magnetic Resonance Imaging in Nonischemic Cardiomyopathy: Utility for Identifying the Ventricular Arrhythmia Substrate. J Am Coll Cardiol, 2009;53(13):1138-45. doi: 10.1016/j.jacc.2008.11.052.

798. Ghannam M, Cochet H, Jais P, Sermesant M, Patel S, Siontis KC, et al. Correlation Between Computer Tomography-derived Scar Topography and Critical Ablation Sites in Postinfarction Ventricular Tachycardia. J Cardiovasc Electrophysiol. 2018;29(3):438-45. doi: 10.1111/jce.13441.

799. Valdigem BP, Silva NJ, Dietrich CO, Moreira D, Sasdelli R, Pinto IM, et al. Accuracy of Epicardial Electroanatomic Mapping and Ablation of Sustained Ventricular Tachycardia Merged with Heart CT Scan in Chronic Chagasic Cardiomyopathy. J Interv Card Electrophysiol. 2010;29(2):119-25. doi: 10.1007/s10840-010-9513-5.

800. Andreu D, Ortiz-Pérez JT, Boussy T, Fernández-Armenta J, Caralt TM, Perea RJ, et al. Usefulness of Contrast-enhanced Cardiac Magnetic Resonance in Identifying the Ventricular Arrhythmia Substrate and the Approach Needed for Ablation. Eur Heart J. 2014;35(20):1316-26. doi: 10.1093/eurheartj/ eht510.
801. Andreu D, Penela D, Acosta J, Fernández-Armenta J, Perea RJ, Soto-Iglesias D, et al. Cardiac Magnetic Resonance-aided Scar Dechanneling: Influence on Acute and Long-term Outcomes. Heart Rhythm. 2017;14(8):1121-8. doi: 10.1016/j.hrthm.2017.05.018.

802. Soto-Iglesias D, Penela D, Jáuregui B, Acosta J, Fernández-Armenta J, Linhart M, et al. Cardiac Magnetic Resonance-guided Ventricular Tachycardia Substrate Ablation. JACC Clin Electrophysiol. 2020;6(4):436-47. doi: 10.1016/j.jacep.2019.11.004.

803. Martinek M, Stevenson WG, Inada K, Tokuda M, Tedrow UB. QRS Characteristics Fail to Reliably Identify Ventricular Tachycardias that Require Epicardial Ablation in Ischemic Heart Disease. J Cardiovasc Electrophysiol. 2012;23(2):188-93. doi: 10.1111/j.1540-8167.2011.02179.x.

804. Sosa E, Scanavacca M, D'Avila A, Pillegge F. A New Technique to Perform Epicardial Mapping in the Electrophysiology Laboratory. J Cardiovasc Electrophysiol. 1996;7(6):531-6. doi: 10.1111/j.1540-8167.1996.tb00559.x.

805. Gunda S, Reddy M, Pillarisetti J, Atoui M, Badhwar N, Swarup V et al. Differences in Complication Rates Between Large Bore Needle and a Long Micropuncture Needle During Epicardial Access: Time to Change Clinical Practice? Circ Arrhythm Electrophysiol. 2015;8(4):890-5. doi: 10.1161/CIRCEP.115.002921.

806. Rogers T, Ratnayaka K, Schenke WH, Faranesh AZ, Mazal JR, O'Neill WW, et al. Intentional Right Atrial Exit for Microcatheter Infusion of Pericardial Carbon Dioxide or Iodinated Contrast to Facilitate Sub-xiphoid Access. Catheter Cardiovasc Interv. 2015;86(2):111-8. doi: 10.1002/ccd.25698.

807. Silberbauer J, Gomes J, O'Nunain S, Kirubakaran S, Hildick-Smith D, McCready J. Coronary Vein Exit and Carbon Dioxide Insufflation to Facilitate Subxiphoid Epicardial Access for Ventricular Mapping and Ablation: First Experience. JACC Clin Electrophysiol. 2017;3(5):514-21. doi: 10.1016/j.jacep.2016.11.002.

808. Di Biase L, Burkhardt JD, Reddy V, Romero J, Neuzil P, Petru J, et al. Initial International Multicenter Human Experience with a Novel Epicardial Access Needle Embedded with a Real-time Pressure/Frequency Monitoring to Facilitate Epicardial Access: Feasibility and Safety. Heart Rhythm. 2017;14(7):981-8. doi: 10.1016/j.hrthm.2017.02.033.

809. Ebrille E, Killu AM, Anavekar NS, Packer DL, Munger TM, McLeod CJ, et al. Successful Percutaneous Epicardial Access in Challenging Scenarios. Pacing Clin Electrophysiol. 2015;38(1):84-90. doi: 10.1111/pace.12503.

810. Halabi M, Faranesh AZ, Schenke WH, Wright VJ, Hansen MS, Saikus CE, et al. Real-time Cardiovascular Magnetic Resonance Subxiphoid Pericardial Access and Pericardiocentesis Using Off-the-shelf Devices in Swine. J Cardiovasc Magn Reson. 2013;15(1):61. doi: 10.1186/1532-429X-15-61.

811. Bradfield JS, Tung R, Boyle NG, Buch E, Shivkumar K. Our Approach to Minimize Risk of Epicardial Access: Standard Techniques with the Addition of Electroanatomic Mapping Guidance. J Cardiovasc Electrophysiol. 2013;24(6):723-7. doi: 10.1111/jce.12058.

812. Scanavacca M. Epicardial Ablation for Ventricular Tachycardia in Chronic Chagas Heart Disease. Arq Bras Cardiol. 2014;102(6):524-8. doi: 10.5935/abc.20140082.

813. Healy C, Viles-Gonzalez JF, Sáenz LC, Soto M, Ramírez JD, D'Avila A. Arrhythmias in Chagasic Cardiomyopathy. Card Electrophysiol Clin. 2015;7(2):251-68. doi: 10.1016/j.ccep.2015.03.016.

814. Silberbauer J, Oloriz T, Maccabelli G, Tsiachris D, Baratto F, Vergara P, et al. Noninducibility and Late Potential Ablation: A Novel Combined Prognostic Procedural End Point for Catheter Ablation of Postinfarction Ventricular Tachycardia. Circ Arrhythm Electrophysiol. 2014;7(3):424-35. doi: 10.1161/CIRCEP.113.001239.

815. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Catheter Ablation of Ventricular Arrhythmias. Heart Rhythm. 2020;17(1):2-154. doi: 10.1016/j.hrthm.2019.03.002.

816. Kudenchuk PJ, Kron J, Walance CG, Cutler JE, Griffith KK, McAnulty JH. Day-to-day Reproducibility of Antiarrhythmic Drug Trials Using Programmed

Extrastimulus Techniques for Ventricular Tachyarrhythmias Associated with Coronary Artery Disease. Am J Cardiol. 1990;66(7):725-30. doi: 10.1016/0002-9149(90)91138-v.

817. Essebag V, Joza J, Nery PB, Doucette S, Nault I, Rivard L, et al. Prognostic Value of Noninducibility on Outcomes of Ventricular Tachycardia Ablation: A VANISH Substudy. JACC Clin Electrophysiol. 2018;4(7):911-9. doi: 10.1016/j.jacep.2018.03.013.

818. Soejima K, Stevenson WG, Maisel WH, Sapp JL, Epstein LM. Electrically Unexcitable Scar Mapping Based on Pacing Threshold for Identification of the Reentry Circuit Isthmus: Feasibility for Guiding Ventricular Tachycardia Ablation. Circulation. 2002;106(13):1678-83. doi: 10.1161/01.cir.0000030187.39852.a7.

819. Arenal A, Glez-Torrecilla E, Ortiz M, Villacastín J, Fdez-Portales J, Sousa E, et al. Ablation of Electrograms with an Isolated, Delayed Component as Treatment of Unmappable Monomorphic Ventricular Tachycardias in Patients with Structural Heart Disease. J Am Coll Cardiol. 2003;41(1):81-92. doi: 10.1016/s0735-1097(02)02623-2.

820. Di Marco A, Sanjuan TO, Paglino G, Baratto F, Vergara P, Bisceglia C, et al. Late Potentials Abolition Reduces Ventricular Tachycardia Recurrence After Ablation Especially in Higher-risk Patients with a Chronic Total Occlusion in an Infarct-related Artery. J Cardiovasc Electrophysiol. 2018;29(8):1119-24. doi: 10.1111/jce.13488.

821. Jaïs P, Maury P, Khairy P, Sacher F, Nault I, Komatsu Y, et al. Elimination of Local Abnormal Ventricular Activities: A New End Point for Substrate Modification in Patients with Scar-related Ventricular Tachycardia. Circulation. 2012;125(18):2184-96. doi: 10.1161/CIRCULATIONAHA.111.043216.

822. Berruezo A, Fernández-Armenta J, Andreu D, Penela D, Herczku C, Evertz R, et al. Scar Dechanneling: New Method for Scar-related Left Ventricular Tachycardia Substrate Ablation. Circ Arrhythm Electrophysiol. 2015;8(2):326-36. doi: 10.1161/CIRCEP.114.002386.

823. Di Biase L, Burkhardt JD, Lakkireddy D, Carbucicchio C, Mohanty S, Mohanty P, et al. Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy: The VISTA Randomized Multicenter Trial. J Am Coll Cardiol. 2015;66(25):2872-82. doi: 10.1016/j.jacc.2015.10.026.

824. Tilz RR, Makimoto H, Lin T, Rillig A, Deiss S, Wissner E, et al. Electrical Isolation of a Substrate After Myocardial Infarction: A Novel Ablation Strategy for Unmappable Ventricular Tachycardias-feasibility and Clinical Outcome. Europace. 2014;16(7):1040-52. doi: 10.1093/europace/eut419.

825. Tzou WS, Frankel DS, Hegeman T, Supple GE, Garcia FC, Santangeli P, et al. Core Isolation of Critical Arrhythmia Elements for Treatment of Multiple Scar-based Ventricular Tachycardias. Circ Arrhythm Electrophysiol. 2015;8(2):353-61. doi: 10.1161/CIRCEP.114.002310.

826. Ren JF, Callans DJ, Michele JJ, Dillon SM, Marchlinski FE. Intracardiac Echocardiographic Evaluation of Ventricular Mural Swelling from Radiofrequency Ablation in Chronic Myocardial Infarction: Irrigated-tip Versus Standard Catheter. J Interv Card Electrophysiol. 2001;5(1):27-32. doi: 10.1023/a:1009849622858.

827. Dickfeld T, Kato R, Zviman M, Nazarian S, Dong J, Ashikaga H, et al. Characterization of Acute and Subacute Radiofrequency Ablation Lesions with Nonenhanced Magnetic Resonance Imaging. Heart Rhythm. 2007;4(2):208-14. doi: 10.1016/j.hrthm.2006.10.019.

828. Romero J, Cerrud-Rodriguez RC, Di Biase L, Diaz JC, Alviz I, Grupposo V, et al. Combined Endocardial-epicardial Versus Endocardial Catheter Ablation Alone for Ventricular Tachycardia in Structural Heart Disease: A Systematic Review and Meta-analysis. JACC Clin Electrophysiol. 2019;5(1):13-24. doi: 10.1016/j.jacep.2018.08.010.

829. Muser D, Liang JJ, Castro SA, Lanera C, Enriquez A, Kuo L, et al. Performance of Prognostic Heart Failure Models in Patients with Nonischemic Cardiomyopathy Undergoing Ventricular Tachycardia Ablation. JACC Clin Electrophysiol. 2019;5(7):801-13. doi: 10.1016/j.jacep.2019.04.001.

830. Simões MV, Romano MMD, Schmidt A, Martins SM, Marin-Neto JA. Chagas Disease Cardiomyopathy. Int J Cardiovasc Sci. 2018;31(2):173-89. doi: 10.5935/2359-4802.20180011.
831. Oliveira JSM, Araujo RRC, Navarro MA, Muccillo G. Cardiac Thrombosis and Thromboembolism in Chronic Chagas' Heart Disease. Am J Cardiol. 1983;52(1):147-51. doi: 10.1016/0002-9149(83)90085-1.

832. Andrade Z, Andrade SG. Patologia. In: Brener, ZA; Andrade, ZA (editors). Trypanosoma cruzi e Doença de Chagas. Rio de Janeiro: Guanabara Koogan; 1979.

833. Anselmi A, Pifano F, Suarez JA, Gurdiel O. Myocardiopathy in Chagas' Disease. J Comparative Study of Pathologic Findings in Chronic Human and Experimental Chagas' Myocarditis. Am Heart J. 1966;72(4):469-81. doi: 10.1016/0002-8703(66)90104-9.

834. Arteaga-Fernández E, Barretto AC, Ianni BM, Mady C, Lopes EA, Vianna CB, et al. Cardiac Thrombosis and Embolism in Patients Having Died of Chronic Chagas Cardiopathy. Arq Bras Cardiol. 1989;52(4):189-92.

835. Fernandes SO, Oliveira MS, Teixeira VP, Almeida HO. Endocardial Thrombosis and Type of Left Vortical Lesion in Chronic Chagasic Patients. Arq Bras Cardiol. 1987;48(1):17-9.

836. Oliveira JS, Oliveira JAM, Frederigue U Jr, Lima Filho EC. Apical Aneurysm of Chagas's Heart Disease. Br Heart J. 1981;46(4):432-7. doi: 10.1136/hrt.46.4.432.

837. Albanesi Filho FM, Gomes Filho JB. Thromboembolism in Patients with Apical Lesion Caused by Chronic Chagasic Cardiopathy. Rev Port Cardiol. 1991;10(1):35-42.

838. Bestetti R. Stroke in a Hospital-derived Cohort of Patients with Chronic Chagas' Disease. Acta Cardiol. 2000;55(1):33-8. doi: 10.2143/AC.55.1.2005715.

839. Braga JC, Labrunie A, Villaça F, Nascimento E, Quijada L. Thromboembolism in Chronic Chagas' Heart Disease. Sao Paulo Med J. 1995;113(2):862-6. doi: 10.1590/s1516-31801995000200019.

840. Nussenzveig I, Wajchemberg BL, Macruz R, Netto AS, Timoner J, Azul LGS. Embolic Cerebral Vascular Accidents in Chronic Chagas' Heart Disease. Arq Neuropsiquiatr. 1953;11(4):386-402. doi: 10.1590/s0004-282x1953000400006.

841. Rocha HP, Andrade ZA. Fenômenos Tromboembólicos Sistêmicos em Portadores de Miocardite Chagásica Crônica. Arq Bras Med. 1955;45:355-64.

842. Carod-Artal FJ, Vargas AP, Horan TA, Nunes LG. Chagasic Cardiomyopathy is Independently Associated with Ischemic Stroke in Chagas Disease. Stroke. 2005;36(5):965-70. doi: 10.1161/01.STR.0000163104.92943.50.

843. Carod-Artal FJ, Gascon J. Chagas Disease and Stroke. Lancet Neurol. 2010;9(5):533-42. doi: 10.1016/S1474-4422(10)70042-9.

844. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-73. doi: 10.1016/j.jacc.2020.04.031.

845. Shaema A, Razuk V, Nicolas J, Beerkens D, Dangs GD. Dois Anos de Pandemia da COVID-19: Implicações para as Salas de Hemodinâmica e suas Práticas Atuais. J Transcat Intervent. 2022;30:eA202203. doi: 10.31160/JOTCI202230A202203.

846. Herrera RN, Díaz E, Pérez R, Cháin S, Sant-Yacumo R, Rodríguez E, et al. The Prothrombotic State in Early Stages of Chronic Chagas' Disease. Rev Esp Cardiol. 2003;56(4):377-82. doi: 10.1016/s0300-8932(03)76881-x.

847. Marcolino MS, Palhares DM, Benjamin EJ, Ribeiro ALP. Atrial Fibrillation: Prevalence in a Large Database of Primary Care Patients in Brazil. Europace. 2015;17(12):1787-90. doi: 10.1093/europace/euv185.

848. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of Subtype of Acute Ischemic Stroke. Definitions for Use in a Multicenter Clinical Trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41. doi: 10.1161/01.str.24.1.35.

849. Lima-Costa MF, Matos DL, Ribeiro ALP. Chagas Disease Predicts 10-year Stroke Mortality in Community-dwelling Elderly: The Bambui Cohort Study of Aging. Stroke. 2010;41(11):2477-82. doi: 10.1161/STROKEAHA.110.588061.

850. World Health Organization. WHO STEPS Stroke Manual: The WHO STEPwise Approach to Stroke Surveillance? Geneva: WHO; 2006.

851. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and Natural History of Clinically Identifiable Subtypes of Cerebral Infarction. Lancet. 1991;337(8756):1521-6. doi: 10.1016/0140-6736(91)93206-o.

852. Carod-Artal FJ, Vargas AP, Melo M, Horan TA. American Trypanosomiasis (Chagas' Disease): An Unrecognised Cause of Stroke. J Neurol Neurosurg Psychiatry. 2003;74(4):516-8. doi: 10.1136/jnnp.74.4.516.

853. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockcroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A Guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):364-467. doi: 10.1161/STR.0000000000000375.

854. Oliveira-Filho J, Martins SC, Pontes-Neto OM, Longo A, Evaristo EF, Carvalho JJ, et al. Guidelines for Acute Ischemic Stroke Treatment: Part I. Arq Neuropsiquiatr. 2012;70(8):621-9. doi: 10.1590/s0004-282x2012000800012.

855. Montanaro VVA, Hora TF, Silva CM, Santos CVV, Lima MIR, Oliveira EMJ, et al. Cerebral Infarct Topography of Atrial Fibrillation and Chagas Disease. J Neurol Sci. 2019;400:10-4. doi: 10.1016/j.jns.2019.03.002.

856. Carod-Artal FJ, Vargas AP, Falcao T. Stroke in Asymptomatic Trypanosoma cruzi-infected Patients. Cerebrovasc Dis. 2011;31(1):24-8. doi: 10.1159/000320248.

857. Carod-Artal FJ. Policy Implications of the Changing Epidemiology of Chagas Disease and Stroke. Stroke. 2013;44(8):2356-60. doi: 10.1161/STROKEAHA.113.000738.

858. Acquatella H, Asch FM, Barbosa MM, Barros M, Bern C, Cavalcante JL, et al. Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration with the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). J Am Soc Echocardiogr. 2018;31(1):3-25. doi: 10.1016/j.echo.2017.10.019.

859. Oliveira MMC, Sampaio EES, Kawaoka JR, Hatem MAB, Câmara EJN. Fernandes AMS, et al. Silent Cerebral Infarctions with Reduced, Mid-range and Preserved Ejection Fraction in Patients with Heart Failure. Arq Bras Cardiol. 2018;111(3):419-22. doi: 10.5935/abc.20180140.

860. Oliveira-Filho J. Stroke and Brain Atrophy in Chronic Chagas Disease Patients: A New Theory Proposition. Dement Neuropsychol. 2009;3(1):22-6. doi: 10.1590/S1980-57642009DN30100005.

861. Cerqueira-Silva T, Gonçalves BM, Pereira CB, Porto LM, Marques ME, Santos LS, et al. Chagas Disease is an Independent Predictor of Stroke and Death in a Cohort of Heart Failure Patients. Int J Stroke. 2022;17(2):180-8. doi: 10.1177/17474930211006284.

862. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):344-418. doi: 10.1161/STR.0000000000000211.

863. Kitano T, Nabeshima Y, Kataoka M, Takeuchi M. Therapeutic Efficacy of Direct Oral Anticoagulants and Vitamin K Antagonists for Left Ventricular Thrombus: Systematic Review and Meta-analysis. PLoS One. 2021;16(7):e0255280. doi: 10.1371/journal.pone.0255280.

864. Montanaro VV, Silva CM, Santos CVV, Lima MI, Negrão EM, Freitas GR. Ischemic Stroke Classification and Risk of Embolism in Patients with Chagas Disease. J Neurol. 2016;263(12):2411-5. doi: 10.1007/s00415-016-8275-0.

865. Mendes FSNS, Mediano MFF, Silva RS, Xavier SS, Brasil PEA, Saraiva RM, et al. Discussing the Score of Cardioembolic Ischemic Stroke in Chagas Disease. Trop Med Infect Dis. 2020;5(2):82. doi: 10.3390/tropicalmed5020082.

866. Marin-Neto JA, Rassi A Jr, Schmidt A. Chronic Chagas Cardiomyopathy: Management and Prognosis. Waltham: UpToDate; 2022.
867. Lage TAR, Tupinambás JT, Pádua LB, Ferreira MO, Ferreira AC, Teixeira AL, et al. Stroke in Chagas Disease: From Pathophysiology to Clinical Practice. Rev Soc Bras Med Trop. 2022;55:e0575. doi: 10.1590/0037-8682-0575-2021.

868. GBD 2019 HIV Collaborators. Global, Regional, and National Sex-specific Burden and Control of the HIV Epidemic, 1990-2019, for 204 Countries and Territories: The Global Burden of Diseases Study 2019. Lancet HIV. 2021;8(10):633-51. doi: 10.1016/S2352-3018(21)00152-1.

869. Pan American Health Organization: Chagas Disease. Washington: PAHO; c2022 [cited 2021 Jun 17]. Available from: https://www.paho.org/en/topics/chagas-disease.

870. Clark EH, Bern C. Chagas Disease in People with HIV: A Narrative Review. Trop Med Infect Dis. 2021;6(4):198. doi: 10.3390/tropicalmed6040198.

871. Del Castillo M, Mendoza G, Oviedo J, Bianco RPP, Anselmo AE, Silva M. AIDS and Chagas' Disease with Central Nervous System Tumor-like Lesion. Am J Med. 1990;88(6):693-4. doi: 10.1016/0002-9343(90)90544-n.

872. Freilij H, Altcheh J, Muchinik G. Perinatal Human Immunodeficiency Virus Infection and Congenital Chagas' Disease. Pediatr Infect Dis J. 1995;14(2):161-2.

873. Shikanai-Yasuda MA, Almeida EA, López MC, Delgado MJP. Chagas Disease: A Parasitic Infection in an Immunosuppressed Host. In: Delgado MJP, Gascón J, editors. Chagas Disease. Zurich: Springer Nature; 2020.

874. Okoye AA, Picker LJ. CD4(+) T-cell Depletion in HIV Infection: Mechanisms of Immunological Failure. Immunol Rev. 2013;254(1):54-64. doi: 10.1111/imr.12066.

875. Wirth JJ, Kierszenbaum F, Sonnenfeld G, Zlotnik A. Enhancing Effects of Gamma Interferon on Phagocytic Cell Association with and Killing of Trypanosoma cruzi. Infect Immun. 1985;49(1):61-6. doi: 10.1128/iai.49.1.61-66.1985.

876. Benchetrit A, Andreani G, Avila MM, Rossi D, Rissio AM, Weissenbacher M, et al. High HIV-Trypanosoma cruzi Coinfection Levels in Vulnerable Populations in Buenos Aires, Argentina. AIDS Res Hum Retroviruses. 2017;33(4):330-1. doi: 10.1089/AID.2016.0068.

877. Dolcini G, Ambrosioni J, Andreani G, Pando MA, Peralta LM, Benetucci J. Prevalence of Human Immunodeficiency Virus (HIV)-Trypanosoma cruzi Co-infection and Injectable-drugs Abuse in a Buenos Aires Health Center. Rev Argent Microbiol. 2008;40(3):164-6.

878. Martins-Melo FR, Ramos AN Jr, Alencar CH, Heukelbach J. Mortality Related to Chagas Disease and HIV/AIDS Coinfection in Brazil. J Trop Med. 2012;2012:534649. doi: 10.1155/2012/534649.

879. Portela-Lindoso AA, Shikanai-Yasuda MA. Chronic Chagas' Disease: From Xenodiagnosis and Hemoculture to Polymerase Chain Reaction. Rev Saude Publica. 2003;37(1):107-15. doi: 10.1590/s0034-89102003000100016.

880. Freitas VL, Silva SC, Sartori AM, Bezerra RC, Westphalen EV, Molina TD, et al. Real-time PCR in HIV/Trypanosoma Cruzi Coinfection with and Without Chagas Disease Reactivation: Association with HIV Viral Load and CD4 Level. PLoS Negl Trop Dis. 2011;5(8):e1277. doi: 10.1371/journal.pntd.0001277.

881. Marcon GEB, Ferreira JJG, Almeida EA, Delicio AM, Pereira MB, Wanderley JDS, et al. Parasite Load Evaluation by qPCR and Blood Culture in Chagas Disease and HIV co-Infected Patients Under Antiretroviral Therapy. PLoS Negl Trop Dis. 2022;16(3):e0010317. doi: 10.1371/journal.pntd.0010317.

882. Brasil. Ministério da Saúde. Manual Técnico para Investigação da Transmissão de Doenças pelo Sangue. Brasília: Ministério da Saúde; 2004.

883. Brasil. Ministério da Saúde. Normas para a Implantação de Unidades de Hemoterapia e Hematologia. Brasília: Ministério da Saúde; 1992.

884. Brasil. Ministério da Saúde. Portaria Nº 158, de 4 de fevereiro de 2016. Redefine o Regulamento Técnico de Procedimentos Hemoterápicos. Brasília: Ministério da Saúde; 2016.

885. Ferreira-Silva MM, Pereira GA, Rodrigues-Júnior V, Meira WS, Basques FV, Langhi-Júnior DM, et al. Chagas Disease: Performance Analysis of Immunodiagnostic Tests Anti-Trypanosoma Cruzi in Blood Donors with Inconclusive Screening Results. Hematol Transfus Cell Ther. 2021;43(4):410-6. doi: 10.1016/j.htct.2020.06.016.

886. Santos EF, Leony LM, Silva ÂAO, Daltro RT, Freitas NEM, Vasconcelos LCM, et al. Assessment of Liaison XL Murex Chagas Diagnostic Performance in Blood Screening for Chagas Disease Using a Reference Array of Chimeric Antigens. Transfusion. 2021;61(9):2701-9. doi: 10.1111/trf.16583.

887. World Health Organization. WHO Consultation on International Biological Reference Preparations for Chagas Diagnostic Tests. Geneva: WHO; 2007.

888. Lopes PS, Ramos EL, Gómez-Hernández C, Ferreira GL, Rezende-Oliveira K. Prevalence of Chagas Disease Among Blood Donor Candidates in Triangulo Mineiro, Minas Gerais State, Brazil. Rev Inst Med Trop Sao Paulo. 2015;57(6):461-5. doi: 10.1590/S0036-46652015000600001.

889. Costa ACD, Rocha EA, Silva Filho JDD, Fidalgo ASOBV, Nunes FMM, Viana CEM, et al. Prevalence of Trypanosoma cruzi Infection in Blood Donors. Arq Bras Cardiol. 2020;115(6):1082-91. doi: 10.3666/abc.20190285.

890. Santana MP, Souza-Santos R, Almeida AS. Prevalence of Chagas Disease Among Blood Donors in Piauí State, Brazil, from 2004 to 2013. Cad Saude Publica. 2018;34(2):e00123716. doi: 10.1590/0102-311X00123716.

891. Lima LM, Alves NP, Barbosa VF, Pimenta GA, Moraes-Souza H, Martins PR. Prevalence of Chagas Disease in Blood Donors at the Uberaba Regional Blood Center, Brazil, from 1995 to 2009. Rev Soc Bras Med Trop. 2012;45(6):723-6. doi: 10.1590/s0037-86822012000600013.

892. Jeong SW, Kim SH, Kang SH, Kim HJ, Yoon CH, Youn TJ, et al. Mortality Reduction with Physical Activity in Patients with and Without Cardiovascular Disease. Eur Heart J. 2019;40(43):3547-55. doi: 10.1093/eurheartj/ehz564.

893. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 Guidelines on Physical Activity and Sedentary Behaviour. Br J Sports Med. 2020;54(24):1451-62. doi: 10.1136/bjsports-2020-102955.

894. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The Physical Activity Guidelines for Americans. JAMA. 2018;320(19):2020-8. doi: 10.1001/jama.2018.14854.

895. Lima MM, Rocha MO, Nunes MC, Sousa L, Costa HS, Alencar MC, et al. A Randomized Trial of the Effects of Exercise Training in Chagas Cardiomyopathy. Eur J Heart Fail. 2010;12(8):866-73. doi: 10.1093/eurjhf/hfq123.

896. Mediano MF, Mendes FS, Pinto VL, Silva GM, Silva PS, Carneiro FM, et al. Cardiac Rehabilitation Program in Patients with Chagas Heart Failure: A Single-arm Pilot Study. Rev Soc Bras Med Trop. 2016;49(3):319-28. doi: 10.1590/0037-8682-0083-2016.

897. Mendes FSNS, Mediano MFF, Souza FCC, Silva PS, Carneiro FM, Holanda MT, et al. Effect of Physical Exercise Training in Patients with Chagas Heart Disease (From the PEACH STUDY). Am J Cardiol. 2020;125(9):1413-20. doi: 10.1016/j.amjcard.2020.01.035.

898. Teza DCB, Ferreira ÉC, Gomes ML. Bowel Frequency and Symptoms of Constipation and its Relation with the Level of Physical Activity in Patients with Chagas Disease. Arq Gastroenterol. 2020;57(2):161-6. doi: 10.1590/S0004-2803.202000000-30.

899. Mediano MFF, Mendes FSNS, Pinto VLM, Silva PSD, Hasslocher-Moreno AM, Sousa AS. Reassessment of Quality of Life Domains in Patients with Compensated Chagas Heart Failure After Participating in a Cardiac Rehabilitation Program. Rev Soc Bras Med Trop. 2017;50(3):404-7. doi: 10.1590/0037-8682-0429-2016.

900. Borges JP, Mendes FSNS, Rangel MVDS, Lopes GO, Silva GMS, Silva PS, et al. Exercise Training Improves Microvascular Function in Patients with Chagas Heart Disease: Data from the PEACH Study. Microvasc Res. 2021;134:104106. doi: 10.1016/j.mvr.2020.104106.

901. Oliveira I, Torrico F, Muñoz J, Gascon J. Congenital Transmission of Chagas Disease: A Clinical Approach. Expert Rev Anti Infect Ther. 2010;8(8):945-56. doi: 10.1586/eri.10.74.
902. Cevallos AM, Hernández R. Chagas’ Disease: Pregnancy and Congenital Transmission. Biomed Res Int. 2014;2014:401864. doi: 10.1155/2014/401864.

903. Carlier Y, Truyens C. Congenital Chagas Disease as an Ecological Model of Interactions Between Trypanosoma cruzi Parasites, Pregnant Women, Placenta and Fetuses. Acta Trop. 2015;151:103-15. doi: 10.1016/j. actatropica.2015.07.016.

904. Bustos PL, Milduberger N, Volta BJ, Perrone AE, Laucella SA, Bua J. Trypanosoma cruzi Infection at the Maternal-fetal Interface: Implications of Parasite Load in the Congenital Transmission and Challenges in the Diagnosis of Infected Newborns. Front Microbiol. 2019;10:1250. doi: 10.3389/ fmicb.2019.01250.

905. Pinazo MJ, Espinosa G, Cortes-Lletget C, Posada EJ, Aldasoro E, Oliveira I, et al. Immunosuppression and Chagas Disease: A Management Challenge. PLoS Negl Trop Dis. 2013;7(1):e1965. doi: 10.1371/journal.pntd.0001965.

906. Vekemans J, Truyens C, Torrico F, Solano M, Torrico MC, Rodriguez P, et al. Maternal Trypanosoma cruzi Infection Upregulates Capacity of Uninfected Neonate Cells to Produce Pro- and Anti-inflammatory Cytokines. Infect Immun. 2000;68(9):5430-4. doi: 10.1128/IAI.68.9.5430-5434.2000.

907. Gürtler RE, Segura EL, Cohen JE. Congenital Transmission of Trypanosoma cruzi Infection in Argentina. Emerg Infect Dis. 2003;9(1):29-32. doi: 10.3201/eid0901.020274.

908. Freilij H, Altcheh J. Congenital Chagas' Disease: Diagnostic and Clinical Aspects. Clin Infect Dis. 1995;21(3):551-5. doi: 10.1093/clinids/21.3.551.

909. Altcheh J, Castro L, Dib JC, Grossmann U, Huang E, Moscatelli G, et al. Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Paediatric Formulation of Nifurtimox in Children Aged 0 to 17 years with Chagas Disease One Year After Treatment (CHICO). PLoS Negl Trop Dis. 2021;15(1):e0008912. doi: 10.1371/journal.pntd.0008912.

910. Roscoe A, Tomey MI, Torregrossa G, Galhardo C Jr, Parhar K, Zochios V. Chagas Cardiomyopathy: A Comprehensive Perioperative Review. J Cardiothorac Vasc Anesth. 2018;32(6):2780-8. doi: 10.1053/j. jvca.2018.04.046.

911. Mets B. Anesthesia for Left Ventricular Assist Device Placement. J Cardiothorac Vasc Anesth. 2000;14(3):316-26.

912. Wafae BG, Silva RMF, Veloso HH. Propofol for Sedation for Direct Current Cardioversion. Ann Card Anaesth. 2019;22(2):113-21. doi: 10.4103/aca. ACA_72_18.

913. Veloso HH, Chaves JC, Sobrinho JJ. Inappropriate Shocks of Implantable Cardioverter-defibrillator During Central Venous Access: A Preventable Complication. Int J Cardiol. 2016;204:61-3. doi: 10.1016/j. ijcard.2015.11.162.

914. Brasil. Ministério da Saúde. Boletim Epidemiológico Especial. Doença pelo Coronavírus COVID-19. Semana Epidemiológica 1 (3 a 9/01). Brasília: Ministério da Saúde; 2021.

915. CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-6. doi: 10.15585/mmwr.mm6912e2.

916. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9. doi: 10.1001/jama.2020.6775.

917. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. doi: 10.1001/jama.2020.2648.

918. Adams ML, Katz DL, Grandpre J. Population-based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. Emerg Infect Dis. 2020;26(8):1831-3. doi: 10.3201/ eid2608.200679.

919. Wang X, Fang X, Cai Z, Wu X, Gao X, Min J, et al. Comorbid Chronic Diseases and Acute Organ Injuries are Strongly Correlated with Disease Severity and Mortality Among COVID-19 Patients: A Systemic Review and Meta-analysis. Research (Wash DC). 2020;2020:2402961. doi: 10.34133/2020/2402961.

920. Marcolino MS, Ziegelmann PK, Souza-Silva MVR, Nascimento IJB, Oliveira LM, Monteiro LS, et al. Clinical Characteristics and Outcomes of Patients Hospitalized with COVID-19 in Brazil: Results from the Brazilian COVID-19 Registry. Int J Infect Dis. 2021;107:300-10. doi: 10.1016/j.ijid.2021.01.019.

921. Planquette B, Le Berre A, Khider L, Yannoutsos A, Gendron N, Torcy M, et al. Prevalence and Characteristics of Pulmonary Embolism in 1042 COVID-19 Patients with Respiratory Symptoms: A Nested Case-control Study. Thromb Res. 2021;197:94-9. doi: 10.1016/j.thromres.2020.11.001.

922. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. Characteristics and Clinical Significance of Myocardial Injury in Patients with Severe Coronavirus Disease 2019. Eur Heart J. 2020;41(22):2070-9. doi: 10.1093/eurheartj/ehaa408.

923. Belarte-Tornero LC, Valdivielso-Moré S, Elcano MV, Solé-González E, Ruiz-Bustillo S, Calvo-Fernández A, et al. Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection. J Clin Med. 2021;10(2):323. doi: 10.3390/jcm10020323.

924. Alvarez-Garcia J, Lee S, Gupta A, Cagliostro M, Joshi AA, Rivas-Lasarte M, et al. Prognostic Impact of Prior Heart Failure in Patients Hospitalized with COVID-19. J Am Coll Cardiol. 2020;76(20):2334-48. doi: 10.1016/j. jacc.2020.09.549.

925. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020;142(1):68-78. doi: 10.1161/CIRCULATIONAHA.120.047549.

926. Vizzoni AG, Varela MC, Sangenis LHC, Hasslocher-Moreno AM, Brasil PEA, Saraiva RM. Ageing with Chagas Disease: An Overview of an Urban Brazilian Cohort in Rio de Janeiro. Parasit Vectors. 2018;11(1):354. doi: 10.1186/ s13071-018-2929-y.

927. Brasil, Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde - SCTIE Departamento de Gestão e Incorporação de Tecnologias e Inovações em Saúde - DIGITIS Coordenação-Geral de Gestão de Tecnologias em Saúde - CGGTS Coordenação de Gestão de Protocolos Clínicos e Diretrizes Terapêuticas - CPCDT. Brasília: Ministério da Saúde; 2020.

928. Costa IBSDS, Bittar CS, Rizk SI, Araújo Filho AE, Santos KAQ, Machado TIV, et al. The Heart and COVID-19: What Cardiologists Need to Know. Arq Bras Cardiol. 2020;114(5):805-16. doi: 10.36660/abc.20200279.

929. Chocair PR, Sabbaga E, Amato Neto V, Shiroma M, Goes GM. Kidney Transplantation: A New Way of Transmitting Chagas Disease. Rev Inst Med Trop Sao Paulo. 1981;23(6):280-2.

930. Huprikar S, Bosserman E, Patel G, Moore A, Pinney S, Anyanwu A, et al. Donor-derived Trypanosoma cruzi Infection in Solid Organ Recipients in the United States, 2001-2011. Am J Transplant. 2013;13(9):2418-25. doi: 10.1111/ajt.12340.

931. Riarte A, Luna C, Sabatiello R, Sinagra A, Schiavelli R, De Rissio A, et al. Chagas' Disease in Patients with Kidney Transplants: 7 Years of Experience 1989-1996. Clin Infect Dis. 1999;29(3):561-7. doi: 10.1086/598634.

932. McCormack L, Quiñónez E, Goldaracena N, Anders M, Rodríguez V, Ganem FO, et al. Liver Transplantation Using Chagas-infected Donors in Uninfected Recipients: A Single-center Experience Without Prophylactic Therapy. Am J Transplant. 2012;12(10):2832-7. doi: 10.1111/j.1600-6143.2012.04160.x.

933. Lattes R, Lasala MB. Chagas Disease in the Immunosuppressed Patient. Clin Microbiol Infect. 2014;20(4):300-9. doi: 10.1111/1469-0691.12585.

934. Casadei D. Chagas' Disease Argentine Collaborative Transplant Consortium. Chagas' Disease and Solid Organ Transplantation. Transplant Proc. 2010;42(9):3354-9. doi: 10.1016/j.transproceed.2010.09.019.

935. Altclas JD, Barcan L, Nagel C, Lattes R, Riarte A. Organ Transplantation and Chagas Disease. JAMA. 2008;299(10):1134-5. doi: 10.1001/ jama.299.10.1134-a.
936. Cicora F, Escurra V, Silguero S, González IM, Roberti JE. Use of Kidneys from Trypanosoma cruzi-infected Donors in Naive Transplant Recipients Without Prophylactic Therapy: The Experience in a High-risk Area. Transplantation. 2014;97(1):e3-4. doi: 10.1097/01.TP0000437673.86339.82.

937. Jardim E, Takayanagui OM. Chagasic meningoencephalitis with detection of Trypanosoma cruzi in the cerebrospinal fluid of an immunodepressed patient. J Trop Med Hyg. 1994;97(6):367-70.

938. Montero M, Mir M, Sulleiro E, Esquivel JLA, López EG, Molina-Morant D, et al. High-dose Benznidazole in a 62-year-old Bolivian Kidney Transplant Recipient with Chagas Central Nervous System Involvement. Int J Infect Dis. 2019;78:103-6. doi: 10.1016/j.ijid.2018.10.014.

939. Salvador F, Sánchez-Montalvá A, Sulleiro E, Moreso F, Berastegui C, Caralt M, et al. Prevalence of Chagas Disease Among Solid Organ-transplanted Patients in a Nonendemic Country. Am J Trop Med Hyg. 2018;98(3):742-6. doi: 10.4269/ajtmh.17-0735.

940. Pinazo MJ, Miranda B, Rodríguez-Villar C, Altclas J, Serra MB, García-Otero EC, et al. Recommendations for Management of Chagas Disease in Organ and Hematopoietic Tissue Transplantation Programs in Nonendemic Areas. Transplant Rev (Orlando). 2011;25(3):91-101. doi: 10.1016/j. tre.2010.12.002.

941. Márquez JDR, Ana Y, Baigorri RE, Stempin CC, Cerban FM. Mammalian Target of Rapamycin Inhibition in Trypanosoma cruzi-infected Macrophages Leads to an Intracellular Profile That Is Detrimental for Infection. Front Immunol. 2018;9:313. doi: 10.3389/fimmu.2018.00313.

942. Santos-Neto LL, Polcheira MF, Castro C, Lima RA, Simaan CK, Corêa-Lima FA. Trypanosoma Cruzi High Parasitemia in Patient with Systemic Lupus Erythematosus. Rev Soc Bras Med Trop. 2003;36(5):613-5.

943. Guariento ME, Carrijo CM, Almeida EA, Magna LA. Perfil Clínico de Idosos Portadores de Doença de Chagas Atendidos em Serviço de Referência. Rev Bras Clin Med. 2011;9(1):20-4.

944. Pereira LS, Freitas EC, Fidalgo AS, Andrade MC, Cândido DS, Filho JDS, et al. Clinical and Epidemiological Profile of Elderly Patients with Chagas Disease Followed Between 2005-2013 by Pharmaceutical Care Service in Ceará State, Northeastern Brazil. Rev Inst Med Trop Sao Paulo. 2015;57(2):145-52. doi: 10.1590/S0036-46652015000200008.

945. Medeiros-Souza P, Santos-Neto LL, Kusano LT, Pereira MG. Diagnosis and Control of Polypharmacy in the Elderly. Rev Saude Publica. 2007;41(6):1049-53. doi: 10.1590/S0034-89102006005000050.

946. Almeida EA, Neto RMB, Guariento ME, Wanderley JS, Souza ML. Clinical Presentation of Chronic Chagas Disease in Elderly Individuals. Rev Soc Bras Med Trop. 2007;40(3):311-5. doi: 10.1590/S0037-86822007000300012.

947. Prata SP, Cunha DF, Cunha SF, Prata SC, Nogueira N. Prevalence of Electrocardiographic Abnormalities in 2,000 Aged and Non-aged Chagasic Patients. Arq Bras Cardiol. 1993;60(6):369-72.

948. Santos JP, Silva R, Ricardo-Silva AH, Verly T, Britto C, Evangelista BBC, et al. Assessing the Entomo-epidemiological Situation of Chagas Disease in Rural Communities in the State of Piauí, Brazilian Semi-arid Region. Trans R Soc Trop Med Hyg. 2020;114(11):820-9. doi: 10.1093/trstmh/traa070.

949. Coura JR, Dias JC. Epidemiology, Control and Surveillance of Chagas Disease: 100 Years After its Discovery. Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):31-40. doi: 10.1590/S0074-02762009000900006.

950. World Health Organization. Integrating Neglected Tropical Diseases into Global Health and Development: Fourth WHO Report on Neglected Tropical Diseases. Geneva: WHO; 2017.

951. Oliveira W Jr. All-around Care for Patients with Chagas Disease: A Challenge for the XXI Century. Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):181-6. doi: 10.1590/S0074-02762009000900024.

952. Gontijo RD, Guariento ME, Almeida EA. Modelo de Atenção ao Chagásico no Sistema Único de Saúde. In: Dias JCP, Coura JR, editors. Clínica e Terapêutica da Doença de Chagas. Rio de Janeiro: Fiocruz; 1997.

953. Brasil. Ministério da Saúde. Boletim Epidemiológico: Panorama da Doença de Chagas no Brasil. Brasília: Ministério da Saúde; 2019.

954. Oliveira D, Chaves GC. Guia para o Fortalecimento e a Formação de Associações de Pessoas Afetadas pela Doença de Chagas. Rio de Janeiro: Fiocruz; 2015.

955. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary Strategies for the Management of Heart Failure Patients at High Risk for Admission: A Systematic Review of Randomized Trials. J Am Coll Cardiol. 2004;44(4):810-9. doi: 10.1016/j.jacc.2004.05.055.

956. Seabra TMR, Ide AC. A Dimensão Psicossocial do Cuidar na Enfermagem. In: Ide AC, Domenico EBL, editors. Ensinando e Aprendendo um Novo Estilo de Cuidar. São Paulo: Atheneu; 2001.

957. Brasil. Ministério da Saúde. Portaria nº 1.061, do Ministério da Saúde do Brasil, de 18 de maio de 2020. Brasília: Ministério da Saúde; 2020.

958. Guiu IC, Mendivelso JC, Essadek HO, Mestre MAG, Albajar-Viñas P, Gómez I, et al. The Catalanian Expert Patient Programme for Chagas Disease: An Approach to Comprehensive Care Involving Affected Individuals. J Immigr Minor Health. 2017;19(1):80-90. doi: 10.1007/s10903-016-0345-y.

959. Sanmartino M, Avaria A, Gómez i Prat J, Parada MC, Albajar-Viñas P. Do Not be Afraid of Us: Chagas Disease as Explained by People Affected by It. Interface (Botucatu). 2015;19(55):1063-75. doi: 10.1590/1807-57622014.1170.

960. Gontijo ED, Guimarães TN, Magnani C, Paixão GM, Dupin S, Paixão LM. Qualidade de Vida dos Portadores de Doença de Chagas. Rev Med Minas Gerais. 2009; 19(4):281-5.

961. Brasil. Governo Federal. Lei n. 7.713, de 22 de dezembro de 1988 [Internet]. Brasília: Casa Civil; 1988 [cited 2013 Jan 25]. Available from: http:www.planalto.gov.brccivil_03leisL7713.htm.

962. Dutra OP, Besser HW, Tridapalli H, Leiria TLL. II Diretriz Brasileira de Cardiopatia Grave. Arq Bras Cardiol. 2006;87(2):223-32. doi: 10.1590/S0066-782X2006001500024.

963. Rassi A Jr, Rassi A, Little WC. Chagas' Heart Disease. Clin Cardiol. 2000;23(12):883-9. doi: 10.1002/clc.4960231205.

964. Nunes MC, Carmo AA, Rocha MO, Ribeiro ALP. Mortality Prediction in Chagas Heart Disease. Expert Rev Cardiovasc Ther. 2012;10(9):1173-84. doi: 10.1586/erc.12.111.

965. Luquetti AO, Porto CS. Aspectos Médico-trabalhistas da Doença de Chagas. In: Dias JCP, Coura JR, editors. Clínica e Terapêutica da Doença de Chagas: Uma Abordagem Prática para o Clínico Geral. Rio de Janeiro: Fiocruz; 1997.

<figure><img src="image_14.png" /></figure>

This is an open-access article distributed under the terms of the Creative Commons Attribution License